Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-151-7 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- other: expert statement
- Adequacy of study:
- key study
- Executive summary:
Absorption
The rather high molecular weight (650.6 - 1299), low water solubility < 0.01 mg/L at 20°C) and high lipophilicity (Log10Pow = 5.5 at 25°C) of ADK STAB FP-900L would be expected to limit its absorption across the skin after topical administration and to limit its absorption after oral administration [ECHA 2017, Chapter R.7c: Endpoint specific guidance]. Consequently the above physicochemical properties of ADK STAB FP-900L are considered to limit its systemic availability both, after topical and after oral administration. This is consistent with the absence of relevant signs of irritation in an acute dermal toxicity study in the rat, skin and eye irritation studies in the rabbit and a Local Lymph Node Assay (LLNA) in mice and with the absence of any sensitization response in the latter study. In addition, in a repeat dose oral toxicity study (OECD 407), in which rats received doses of up to 1000 mg/kg/day on 28 consecutive days, findings indicative of absorption or systemic exposure were not evident after 4 treatment weeks and also not after a subsequent 2-week treatment free recovery period.
No data is available on absorption after inhalation. However, inhalation of any vapour from ADK STAB FP-900L is an unlikely route of human exposure, because the substance has a very low vapour pressure (5.3 x 10E-5 Pa at 25°C) and decomposes without boiling at high temperatures (≥ ca. 260°C). Exposure of humans to an inhalable aerosol of ADK STAB FP-900L is also unlikely because the substance is a viscous liquid.
From the absence of any toxicity in all available toxicity studies and the absence of any relevant adverse effects in in-vitro genotoxicity tests or on algae, daphnia, fish or bacteria in ecotoxicology studies, and from the fact of not being readily biodegradable and not predicted as oxidising, it is concluded that ADK STAB FP-900L may behave quasi-inert in biological systems.
Distribution, metabolism, and excretion
All available study results gave no indication regarding the metabolic pathway, distribution or excretion of ADK STAB FP-900L.
Bioaccumulation
The substance is not expected to have a bioaccumulation potential. No effects were observed in the sub-chronic oral toxicity study after 28 days of repeated dosing at a level of 1000 mg/kg body weight/day. In a study for determination of bioaccumulation in fish no accumulation potential was evident (BCF < 100).
Reference
Description of key information
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Absorption
The rather high molecular weight (650.6 - 1299), low water solubility < 0.01 mg/L at 20°C) and high lipophilicity (Log10Pow = 5.5 at 25°C) of ADK STAB FP-900L would be expected to limit its absorption across the skin after topical administration and to limit its absorption after oral administration [ECHA 2017, Chapter R.7c: Endpoint specific guidance]. Consequently the above physicochemical properties of ADK STAB FP-900L are considered to limit its systemic availability both, after topical and after oral administration. This is consistent with the absence of relevant signs of irritation in an acute dermal toxicity study in the rat, skin and eye irritation studies in the rabbit and a Local Lymph Node Assay (LLNA) in mice and with the absence of any sensitization response in the latter study. In addition, in a repeat dose oral toxicity study (OECD 407), in which rats received doses of up to 1000 mg/kg/day on 28 consecutive days, findings indicative of absorption or systemic exposure were not evident after 4 treatment weeks and also not after a subsequent 2-week treatment free recovery period.
No data is available on absorption after inhalation. However, inhalation of any vapour from ADK STAB FP-900L is an unlikely route of human exposure, because the substance has a very low vapour pressure (5.3 x 10E-5 Pa at 25°C) and decomposes without boiling at high temperatures (≥ ca. 260°C). Exposure of humans to an inhalable aerosol of ADK STAB FP-900L is also unlikely because the substance is a viscous liquid.
From the absence of any toxicity in all available toxicity studies and the absence of any relevant adverse effects in in-vitro genotoxicity tests or on algae, daphnia, fish or bacteria in ecotoxicology studies, and from the fact of not being readily biodegradable and not predicted as oxidising, it is concluded that ADK STAB FP-900L may behave quasi-inert in biological systems.
Distribution, metabolism, and excretion
All available study results gave no indication regarding the metabolic pathway, distribution or excretion of ADK STAB FP-900L.
Bioaccumulation
The substance is not expected to have a bioaccumulation potential. No effects were observed in the sub-chronic oral toxicity study after 28 days of repeated dosing at a level of 1000 mg/kg body weight/day. In a study for determination of bioaccumulation in fish no accumulation potential was evident (BCF < 100).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.